drugset / Trial / NCT02652429

Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH

NCT02652429

Phase 3 Unknown 22 enrolled Bellerophon Pulse Technologies
NaSingle-groupOpen-labelTreatment

Summary

An Open-Label Long-Term Safety Study of Inhaled Nitric Oxide (iNO) for Pulmonary Arterial Hypertension (PAH)

Timeline

Start
2016-03
Primary completion
2023-04
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitric Oxide Other / unclassified 75 ug/kg Inhaled